News | November 29, 2022
Fredun Pharmaceuticals signs two large contracts
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
The only definitive way to diagnose and stage lung cancers is through biopsies
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Acquisition expands Merck’s growing hematology portfolio
Subscribe To Our Newsletter & Stay Updated
